Table 1.
Baseline patient and tumor characteristics of patients enrolled on the American College of Surgeons Oncology Group Z0011 trial. (Data from Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011;305:569–75.)
| Characteristic | ALND (n=420) | SLND alone (n=436) |
|---|---|---|
|
| ||
| Age in years, median (range) | 56 (24–92) | 54 (25–90) |
|
| ||
| Clinical T stage | ||
| T1 | 284 (68%) | 303 (71%) |
| T2 | 134 (32%) | 126 (29%) |
| missing | 2 | 7 |
|
| ||
| Tumor size, median (range), cm | 1.7 (0.4–7.0) | 1.6 (0.0–5.0) |
|
| ||
| ER positive | 317 (83%) | 324 (83%) |
|
| ||
| LVI | ||
| Present | 129 (41%) | 113 (35%) |
| Absent | 189 (59%) | 208 (65%) |
| Missing | 102 | 115 |
|
| ||
| Grade* | ||
| 1 | 71 (22%) | 81 (26%) |
| 2 | 158 (49%) | 148 (47%) |
| 3 | 94 (29%) | 87 (27%) |
| Missing | 97 | 120 |
|
| ||
| Histology | ||
| Infiltrating ductal | 344 (83%) | 356 (84%) |
| Infiltrating lobular | 27 (6%) | 36 (8.5%) |
| Other | 45 (11%) | 32 (7.5%) |
| Missing | 4 | 12 |
|
| ||
| Lymph node metastases | ||
| 0 | 4 (1%) | 29 (7%) |
| 1 | 199 (58%) | 295 (71%) |
| 2 | 68 (20%) | 76 (18%) |
| 3 | 25 (7%) | 11 (3%) |
| ≥ 4 | 47 (14%) | 4 (1%) |
| Missing | 77 | 21 |
ER = estrogen receptor
LVI = lymphovascular invasion
ALND = axillary lymph node dissection
SLND = sentinel lymph node dissection
*
Grade was determined using the modified Bloom-Richardson score